content_top
34 companies, 1 interpreter! Insight, foresight
and recommendation 

Capricor (CAPR)

9.89
-0.20
(-20.00%)
 Sep 11, 4:00PM EDT
content_middle

Capricor Therapeutics (CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders.

CAPR’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. The HOPE-Duchenne trial was funded in part by the California Institute for Regenerative Medicine.

CAPR is one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

The company was founded in 2005 and is headquartered in Beverly Hills, California.

Company Website
Previous Close: 
10.09
Open: 
1.00
Bid: 
1.00
Ask: 
1.05
1yr Target Price: 
2.15
Day's Range: 
1.00 - 1.03
52wk Range: 
3.52 - 23.40
Volume: 
42426
Average Daily Volume: 
1353650
Market Capitalization: 
0.00M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
0.00M
content_right

Pages